NCT04962724 - A Study to Evaluate the Absorption, Metabolism, and Excretion and Absolute Bioavailability of Xevinapant in Healthy Male Participants | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 2, 2021

Primary Completion Date

November 9, 2021

Study Completion Date

November 9, 2021

Conditions

Healthy Volunteers

Interventions

DRUG

Radiolabelled Xevinapant 200 mg (Oral Solution)

\[14C\]-Xevinapant 200 mg administered as an oral solution on Day 1 of Part 1, containing approximately 100 microcurie (μCi) \[3.7 megabecquerel (MBq)\] in fasted conditions.

DRUG

Radiolabelled Xevinapant 100 μg (IV Solution)

100 μg \[14C\]-xevinapant single dose administered as an IV bolus on Day 1, containing approximately 0.2 μCi \[7.4 kilobecquerel (kBq)\].

DRUG

Xevinapant 200 mg (Oral Solution)

Xevinapant 200 mg administered as an oral solution on Day 1 of Part 2 in fasted conditions

Trial Locations (1)

LS2 9LH

Labcorp Clinical Research Unit, Leeds